Mifeprex Labeling Change Not A Move Toward Product Withdrawal, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Decision to strengthen warnings on the abortifacient was a “routine action” resulting from reports of serious adverse events, CDER Acting Director Galson says. “There was absolutely no political pressure on this,” he says, calling the labeling revision “science-based.”
You may also be interested in...
Danco Revises Mifeprex Labeling To Add Post-Marketing Adverse Reactions
Adverse events for the abortifacient include allergic reactions, hypotension, light-headedness, shortness of breath and tachycardia. Reports of serious infections and ruptured ectopic pregnancies prompted FDA to strengthen Mifeprex’ “black box” warning in November.
Danco Revises Mifeprex Labeling To Add Post-Marketing Adverse Reactions
Adverse events for the abortifacient include allergic reactions, hypotension, light-headedness, shortness of breath and tachycardia. Reports of serious infections and ruptured ectopic pregnancies prompted FDA to strengthen Mifeprex’ “black box” warning in November.
FDA Revises Mifeprex “Black Box” To Warn About Infection, Bleeding
Revised labeling resulted from reports of “serious bacterial infection, bleeding, ectopic pregnancies that have ruptured, and death,” FDA says. The new language is significantly stronger than the original black box, which focused on the potential failure of Danco’s mifepristone to result in a complete abortion.